Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
Anaplastic thyroid carcinoma (ATC) is one rare type of thyroid carcinoma without standard systemic treatment for advanced disease. Recent evidence has demonstrated promising efficacy of immune checkpoint inhibitors, particularly those targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X241313084 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583715053633536 |
|---|---|
| author | Shanmin Fan Yang Yuan Yanfang Su Die Sang |
| author_facet | Shanmin Fan Yang Yuan Yanfang Su Die Sang |
| author_sort | Shanmin Fan |
| collection | DOAJ |
| description | Anaplastic thyroid carcinoma (ATC) is one rare type of thyroid carcinoma without standard systemic treatment for advanced disease. Recent evidence has demonstrated promising efficacy of immune checkpoint inhibitors, particularly those targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1), in a variety of solid tumors. However, there have been no research of immune checkpoint inhibitors plus chemotherapy in ATC. Here, we present the case of a 37-year-old man with metastatic ATC with positive PD-L1 expression, who achieved long-term remission of 34 months after later-line treatment with zimberelimab (a PD-1 inhibitor) and nab-paclitaxel, followed by single-agent zimberelimab maintenance therapy. After three cycles of the combination treatment, the thyroid lesion and the liver metastases shrank dramatically, leading to the best overall response of partial remission. PD-L1 expression may serve as a potential biomarker for tumor response to immune checkpoint inhibitors in ATC. Our review highlights the need for further studies investigating the role of PD-L1 status as biomarker to predict the prognosis of immunotherapy in the treatment of ATC. |
| format | Article |
| id | doaj-art-5621684ee48e493bbd44451af7d6d15c |
| institution | Kabale University |
| issn | 2050-313X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj-art-5621684ee48e493bbd44451af7d6d15c2025-01-28T07:03:25ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-01-011310.1177/2050313X241313084Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case reportShanmin Fan0Yang Yuan1Yanfang Su2Die Sang3Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, ChinaDepartment of Pathology, Emergency General Hospital, Beijing, ChinaDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, ChinaDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, ChinaAnaplastic thyroid carcinoma (ATC) is one rare type of thyroid carcinoma without standard systemic treatment for advanced disease. Recent evidence has demonstrated promising efficacy of immune checkpoint inhibitors, particularly those targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1), in a variety of solid tumors. However, there have been no research of immune checkpoint inhibitors plus chemotherapy in ATC. Here, we present the case of a 37-year-old man with metastatic ATC with positive PD-L1 expression, who achieved long-term remission of 34 months after later-line treatment with zimberelimab (a PD-1 inhibitor) and nab-paclitaxel, followed by single-agent zimberelimab maintenance therapy. After three cycles of the combination treatment, the thyroid lesion and the liver metastases shrank dramatically, leading to the best overall response of partial remission. PD-L1 expression may serve as a potential biomarker for tumor response to immune checkpoint inhibitors in ATC. Our review highlights the need for further studies investigating the role of PD-L1 status as biomarker to predict the prognosis of immunotherapy in the treatment of ATC.https://doi.org/10.1177/2050313X241313084 |
| spellingShingle | Shanmin Fan Yang Yuan Yanfang Su Die Sang Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report SAGE Open Medical Case Reports |
| title | Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report |
| title_full | Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report |
| title_fullStr | Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report |
| title_full_unstemmed | Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report |
| title_short | Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report |
| title_sort | advanced anaplastic thyroid carcinoma with positive expression of pd l1 response to immune checkpoint inhibitors a case report |
| url | https://doi.org/10.1177/2050313X241313084 |
| work_keys_str_mv | AT shanminfan advancedanaplasticthyroidcarcinomawithpositiveexpressionofpdl1responsetoimmunecheckpointinhibitorsacasereport AT yangyuan advancedanaplasticthyroidcarcinomawithpositiveexpressionofpdl1responsetoimmunecheckpointinhibitorsacasereport AT yanfangsu advancedanaplasticthyroidcarcinomawithpositiveexpressionofpdl1responsetoimmunecheckpointinhibitorsacasereport AT diesang advancedanaplasticthyroidcarcinomawithpositiveexpressionofpdl1responsetoimmunecheckpointinhibitorsacasereport |